

# Diane C Bodurka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/815175/publications.pdf>

Version: 2024-02-01

144  
papers

10,808  
citations

38742

50  
h-index

31849

101  
g-index

150  
all docs

150  
docs citations

150  
times ranked

9619  
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7703-7720.	1.6	1,674
2	Grading Ovarian Serous Carcinoma Using a Two-Tier System. <i>American Journal of Surgical Pathology</i> , 2004, 28, 496-504.	3.7	592
3	Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2006, 98, 172-180.	6.3	363
4	Quality of Life and Sexual Functioning in Cervical Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2005, 23, 7428-7436.	1.6	360
5	Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. <i>Gynecologic Oncology</i> , 2004, 95, 133-138.	1.4	309
6	Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. <i>Supportive Care in Cancer</i> , 2005, 13, 219-227.	2.2	263
7	Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2006, 108, 361-368.	2.4	242
8	Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. <i>Gynecologic Oncology</i> , 2009, 114, 48-52.	1.4	234
9	Association of Low-Grade Endometrioid Carcinoma of the Uterus and Ovary With Undifferentiated Carcinoma: A New Type of Dedifferentiated Carcinoma?. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 52-58.	1.4	215
10	Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. <i>Obstetrics and Gynecology</i> , 2002, 99, 3-10.	2.4	204
11	Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , 2008, 108, 510-514.	1.4	203
12	Undifferentiated Carcinoma of the Endometrium. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1316-1321.	3.7	187
13	Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. <i>Journal of Clinical Oncology</i> , 2017, 35, 1103-1111.	1.6	186
14	Carcinoma of the Lower Uterine Segment: A Newly Described Association With Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2008, 26, 5965-5971.	1.6	184
15	Predictors of Sexual Functioning in Ovarian Cancer Patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 881-889.	1.6	180
16	Correlation of Smoking History and Other Patient Characteristics With Major Complications of Pelvic Radiation Therapy for Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3651-3657.	1.6	174
17	An Assessment of the Utilization of Complementary and Alternative Medication in Women With Gynecologic or Breast Malignancies. <i>Journal of Clinical Oncology</i> , 2004, 22, 671-677.	1.6	170
18	Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , 2012, 125, 661-666.	1.4	166

#	ARTICLE	IF	CITATIONS
19	Generalizability of cancer clinical trial results. <i>Cancer</i> , 2006, 106, 2452-2458.	4.1	162
20	Uterine Epithelioid Leiomyosarcomas With Clear Cells. <i>American Journal of Surgical Pathology</i> , 2004, 28, 244-249.	3.7	144
21	Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. <i>Obstetrics and Gynecology</i> , 2018, 131, 109-116.	2.4	143
22	Uterine smooth muscle tumor of uncertain malignant potential: A retrospective analysis. <i>Gynecologic Oncology</i> , 2009, 113, 324-326.	1.4	138
23	Reclassification of serous ovarian carcinoma by a 2-tier system. <i>Cancer</i> , 2012, 118, 3087-3094.	4.1	135
24	Predictors of final histology in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2004, 95, 463-468.	1.4	133
25	Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer <sup>1</sup> . <i>Journal of the American College of Surgeons</i> , 2004, 199, 388-393.	0.5	132
26	Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 4098-4104.	7.0	132
27	Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 104, 100-103.	1.4	118
28	Significantly Greater Expression of ER, PR, and ECAD in Advanced-Stage Low-Grade Ovarian Serous Carcinoma as Revealed by Immunohistochemical Analysis. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 404-409.	1.4	115
29	Pelvic fractures after radiotherapy for cervical cancer. <i>Cancer</i> , 2010, 116, 625-630.	4.1	106
30	Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor <sup>2</sup> in ovarian serous carcinoma and normal ovarian surface epithelium. <i>Cancer</i> , 2003, 98, 758-764.	4.1	104
31	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2006, 101, 126-131.	1.4	98
32	Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 291-297.	1.6	95
33	Are women ready for the HPV vaccine?. <i>Gynecologic Oncology</i> , 2006, 103, 151-154.	1.4	94
34	Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. <i>Journal of Clinical Oncology</i> , 2015, 33, 2675-2682.	1.6	91
35	Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA). <i>Cancer Treatment Reviews</i> , 2009, 35, 69-78.	7.7	87
36	Overall survival after pelvic exenteration for gynecologic malignancy. <i>Gynecologic Oncology</i> , 2014, 134, 546-551.	1.4	84

#	ARTICLE	IF	CITATIONS
37	Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. American Journal of Obstetrics and Gynecology, 2009, 200, 288.e1-288.e8.	1.3	79
38	Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. Gynecologic Oncology, 2003, 90, 625-628.	1.4	73
39	Patient Preferences Regarding Side Effects of Chemotherapy for Ovarian Cancer: Do They Change over Time?. Gynecologic Oncology, 2002, 87, 118-128.	1.4	70
40	Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecologic Oncology, 2007, 105, 470-474.	1.4	70
41	Comparison of the clinical behavior of newly diagnosed stages IIâ€“IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecologic Oncology, 2007, 105, 625-629.	1.4	69
42	Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. Gynecologic Oncology, 2004, 94, 746-753.	1.4	67
43	A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecologic Oncology, 2004, 94, 442-448.	1.4	66
44	Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth. Clinical Cancer Research, 2008, 14, 5437-5446.	7.0	61
45	Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecologic Oncology, 2013, 130, 323-328.	1.4	60
46	Survivors of gynecologic malignancies: impact of treatment on health and well-being. Journal of Cancer Survivorship, 2016, 10, 261-270.	2.9	59
47	Perioperative blood transfusion in gynecologic oncology surgery: Analysis of the National Surgical Quality Improvement Program Database. Gynecologic Oncology, 2015, 136, 65-70.	1.4	58
48	Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. American Journal of Obstetrics and Gynecology, 2021, 224, 191.e1-191.e15.	1.3	56
49	Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. Obstetrics and Gynecology, 2006, 108, 515-520.	2.4	55
50	Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecologic Oncology, 2008, 110, 65-70.	1.4	55
51	Social-cognitive theory predictors of exercise behavior in endometrial cancer survivors.. Health Psychology, 2013, 32, 1137-1148.	1.6	55
52	Sexual Function after Gynecologic Cancer. Obstetrics and Gynecology Clinics of North America, 2006, 33, 621-630.	1.9	53
53	Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecologic Oncology, 2004, 92, 586-591.	1.4	50
54	Quality of life for patients with epithelial ovarian cancer. Nature Clinical Practice Oncology, 2007, 4, 18-29.	4.3	50

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness Analysis of Diagnosis and Management of Cervical Squamous Intraepithelial Lesions. <i>Obstetrics and Gynecology</i> , 1998, 91, 270-277.	2.4	48
56	Î2-catenin nuclear localization is associated with grade in ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2003, 88, 363-368.	1.4	48
57	A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 6840-6846.	7.0	47
58	Cervical cancer. <i>Cancer</i> , 2003, 98, 2009-2014.	4.1	45
59	A uterine leiomyosarcoma that became positive for HMB45 in the metastasis. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 43-45.	1.3	44
60	Comparison of Treatment Tolerance and Outcomes in Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy in a Prospective Randomized Trial or With Standard Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 118-125.	0.8	43
61	Low-grade serous primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2011, 121, 482-486.	1.4	42
62	Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. <i>Palliative and Supportive Care</i> , 2009, 7, 299-306.	1.0	39
63	Does Death Anxiety Affect End-of-Life Care Discussions?. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1521-1526.	2.5	39
64	Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 553-558.	1.4	39
65	End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1829-1835.	1.6	36
66	Sarcomatoid carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2003, 90, 23-28.	1.4	35
67	Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: A feasibility study. <i>Gynecologic Oncology</i> , 2014, 132, 149-153.	1.4	35
68	Mentorship and Productivity among Gynecologic Oncology Fellows. <i>Journal of Cancer Education</i> , 2003, 18, 15-19.	1.3	34
69	How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. <i>Cancer Treatment Reviews</i> , 2016, 46, 1-8.	7.7	34
70	Growth Suppression of Human Ovarian Cancer Cell Lines by the Introduction of a p16 Gene via a Recombinant Adenovirus. <i>Gynecologic Oncology</i> , 1999, 73, 27-34.	1.4	33
71	Endovascular Management of Ureteralâ€Iliac Artery Fistulae with Wallgraft Endoprostheses. <i>Gynecologic Oncology</i> , 2002, 85, 212-217.	1.4	33
72	Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. <i>Cancer</i> , 2011, 117, 3741-3749.	4.1	33

#	ARTICLE	IF	CITATIONS
73	Long-term survival among 5-year survivors of adolescent and young adult cancer. <i>Cancer</i> , 2020, 126, 3708-3718.	4.1	33
74	A phase II study of irifolven in women with recurrent and heavily pretreated ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 101, 55-61.	1.4	32
75	Perception of screening and risk reduction surgeries in patients tested for a <i>BRCA</i> deleterious mutation. <i>Cancer</i> , 2009, 115, 1598-1604.	4.1	31
76	Improved survival in non-Ashkenazi Jewish ovarian cancer patients with <i>BRCA1</i> and <i>BRCA2</i> gene mutations. <i>Gynecologic Oncology</i> , 2011, 121, 358-363.	1.4	30
77	Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. <i>Gynecologic Oncology</i> , 2014, 135, 244-248.	1.4	30
78	Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 138, 388-393.	1.4	30
79	A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2014, 134, 478-485.	1.4	28
80	The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTIONS in Gynecologic Oncology. <i>Annals of Surgical Oncology</i> , 2017, 24, 362-368.	1.5	28
81	Trends among Gynecologic Oncology Inpatient Deaths: Is End-of-Life Care Improving?. <i>Gynecologic Oncology</i> , 2002, 85, 356-361.	1.4	27
82	Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. <i>Gynecologic Oncology</i> , 2007, 107, 140-142.	1.4	27
83	Dying well: How equal is end of life care among gynecologic oncology patients?. <i>Gynecologic Oncology</i> , 2016, 140, 295-300.	1.4	26
84	Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?. <i>Gynecologic Oncology</i> , 2011, 120, 229-232.	1.4	24
85	A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage Iâ€“III A (1988) uterine papillary serous carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2013, 129, 304-309.	1.4	24
86	Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2016, 142, 525-530.	1.4	24
87	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. <i>BMC Cancer</i> , 2008, 8, 101.	2.6	22
88	Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. <i>Cancer</i> , 2011, 117, 2659-2667.	4.1	22
89	Symptom research in gynecologic oncology: A review of available measurement tools. <i>Gynecologic Oncology</i> , 2010, 119, 384-389.	1.4	21
90	Capturing the Patient's Experience: Using Qualitative Methods to Develop a Measure of Patient-Reported Symptom Burden: An Example From Ovarian Cancer. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 837-845.	1.2	20

#	ARTICLE	IF	CITATIONS
91	Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. <i>Gynecologic Oncology</i> , 2018, 149, 484-490.	1.4	20
92	Surgical education and training program development for gynecologic oncology: American perspective. <i>Gynecologic Oncology</i> , 2009, 114, S47-S51.	1.4	19
93	What Is the Real Rate of Surgical Site Infection?. <i>Journal of Oncology Practice</i> , 2016, 12, e878-e883.	2.5	19
94	Does Tamoxifen Use Affect Prognosis in Breast Cancer Patients Who Develop Endometrial Cancer?. <i>Obstetrics and Gynecology</i> , 2004, 104, 255-260.	2.4	18
95	Cancer-Associated Retinopathy in Neuroendocrine Carcinoma of the Fallopian Tube. <i>Journal of Neuro-Ophthalmology</i> , 2010, 30, 252-254.	0.8	18
96	Targeting those with decreased meaning and peace: a supportive care opportunity. <i>Supportive Care in Cancer</i> , 2015, 23, 2025-2032.	2.2	18
97	Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 1985-1991.	2.2	18
98	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.	1.4	18
99	Laparoscopy training in gynecologic oncology fellowship programs. <i>Gynecologic Oncology</i> , 2008, 111, 197-201.	1.4	17
100	Fighting cancer together: Development and implementation of shared medical appointments to standardize and improve chemotherapy education. <i>Gynecologic Oncology</i> , 2016, 140, 114-119.	1.4	17
101	Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology. <i>Gynecologic Oncology</i> , 2019, 153, 597-603.	1.4	16
102	Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2005, 97, 840-844.	1.4	15
103	Patient Preferences for Side Effects Associated With Cervical Cancer Treatment. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1077-1084.	2.5	15
104	Gynecologic cancer survivor preferences for long-term surveillance. <i>BMC Cancer</i> , 2018, 18, 375.	2.6	15
105	Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience. <i>Gynecologic Oncology</i> , 2010, 117, 467-472.	1.4	14
106	Implementation of a standardized electronic tool improves compliance, accuracy, and efficiency of trainee-to-trainee patient care handoffs after complex general surgical oncology procedures. <i>Surgery</i> , 2017, 161, 869-875.	1.9	14
107	Quality of life and gynecologic malignancies. <i>Current Oncology Reports</i> , 2005, 7, 459-465.	4.0	13
108	Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. <i>Gynecologic Oncology</i> , 2017, 147, 497-502.	1.4	12

#	ARTICLE	IF	CITATIONS
109	Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. International Journal of Gynecological Cancer, 2017, 27, 1350-1359.	2.5	12
110	Quality of life in cervix cancer survivorsâ€”What matters the most in the long-term?. Gynecologic Oncology, 2005, 97, 307-309.	1.4	11
111	A Phase II trial of oral capecitabine in patients with platinum â€” and taxane â€” refractory ovarian, fallopian tube, or peritoneal cancer. Gynecologic Oncology, 2006, 102, 468-474.	1.4	11
112	Effects of music relaxation video on pain and anxiety for women with gynaecological cancer receiving intracavitary brachytherapy: a randomised controlled trial. Journal of Research in Nursing, 2015, 20, 129-144.	0.9	11
113	Women's cancer survivorship: Time to gear up!. Gynecologic Oncology, 2012, 124, 377-378.	1.4	10
114	Lifestyle Modification in Cervical Cancer Survivors: An Ongoing Need. International Journal of Gynecological Cancer, 2014, 24, 570-575.	2.5	10
115	Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecologic Oncology, 2019, 152, 514-521.	1.4	10
116	Alveolar soft part sarcoma of the cervix: case report and literature review. Archives of Gynecology and Obstetrics, 2009, 279, 263-265.	1.7	9
117	The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. International Journal of Gynecological Cancer, 2017, 27, 838-846.	2.5	9
118	E-motions: Email for Written Emotional Expression. Journal of Clinical Oncology, 2002, 20, 3352-3355.	1.6	8
119	Handoff Tool Enabling Standardized Transitions Between the Emergency Department and the Hospitalist Inpatient Service at a Major Cancer Center. American Journal of Medical Quality, 2018, 33, 629-636.	0.5	8
120	Evaluation of patient chemotherapy education in a gynecology oncology center. Supportive Care in Cancer, 2004, 12, 577-83.	2.2	7
121	Unverifiable Accomplishments and Publications on Applications for Gynecologic Oncology Fellowships. Obstetrics and Gynecology, 2012, 119, 504-508.	2.4	7
122	Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. American Journal of Obstetrics and Gynecology, 2014, 210, 257.e1-257.e6.	1.3	7
123	Uterine Sarcomas. , 2006, , 125-147.		7
124	Willingness of pregnant women to vaccinate themselves and their newborns with the HPV vaccine. Vaccine, 2011, 29, 4618-4622.	3.8	6
125	Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints. Gynecologic Oncology, 2017, 145, 562-568.	1.4	6
126	How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Gynecologic Oncology, 2019, 152, 452-458.	1.4	6



#	ARTICLE	IF	CITATIONS
127	Concurrent Chemoradiation in the Routine Management of Patients With Cervical Cancer: Does Marital Status Matter?. International Journal of Gynecological Cancer, 2009, 19, 1107-1112.	2.5	4
128	Ethics Consultation on a Gynecologic Oncology Service: An Opportunity for Physician Education. Journal of Cancer Education, 2011, 26, 183-187.	1.3	4
129	Prospective Study of Symptom Assessment Among Patients With Cervical Cancer During Concurrent Chemoradiotherapy With Weekly Cisplatin or Every-3-Week Cisplatin and 5-Fluorouracil. International Journal of Gynecological Cancer, 2013, 23, 1520-1527.	2.5	4
130	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 2021, 161, 104-112.	1.4	4
131	Survival after intestinal perforation: Can it be predicted?. Gynecologic Oncology, 2009, 115, 349-353.	1.4	3
132	Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies. Journal of Oncology Pharmacy Practice, 2017, 23, 121-127.	0.9	3
133	Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. Journal of Oncology Practice, 2019, 15, e1092-e1097.	2.5	3
134	What's New in Gynecology and Obstetrics. Journal of the American College of Surgeons, 2005, 201, 265-274.	0.5	2
135	Human papillomavirus vaccine acceptability: Is multimedia education ready for prime time?. Gynecologic Oncology, 2010, 118, 101-102.	1.4	2
136	Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. International Journal of Gynecological Cancer, 2020, 30, 1768-1774.	2.5	2
137	An Integrated Approach to Selecting a Prepared Medical Decision-Maker. Journal of Pain and Symptom Management, 2021, 61, 1305-1310.	1.2	2
138	Quality of Life in the Gynecologic Cancer Patient. , 2004, , 785-794.		2
139	Tubo-Ovarian Abscess Following Small Bowel Perforation Caused by Entamoeba histolytica. Journal of Pelvic Medicine & Surgery, 2007, 13, 27-28.	0.1	1
140	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. Journal of Cancer Education, 2020, , 1.	1.3	1
141	Caring for cancer patients in the future: a perfect storm on the horizon?. Oncology, 2010, 24, 1351-2.	0.5	1
142	Gynecologic Cancer Survivorship Management. , 2015, , 125-143.		0
143	Diagnosis and Management of Stage II Endometrial Cancer. , 2015, , 293-305.		0
144	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 232-237.	2.5	0